Eligibility AZD1152 and LDAC in AML
ODM derived from http://clinicaltrials.gov/ct2/show/record/NCT00952588

Eligibility AZD1152 and LDAC in AML

  1. StudyEvent: Eligibility
    1. Eligibility AZD1152 and LDAC in AML
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
UMLS CUI
Item Group
Inclusion criteria
C1512693
consent
Item
Provision of written informed consent
boolean
C0021430
Age
Item
Newly diagnosed male or female patients aged 60 and over
boolean
C0001779
AML
Item
De Novo or Secondary AML
boolean
C0023467
Patient not eligible for Induction therapy
Item
Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia
boolean
C3242266
C0600558
Item Group
Exclusion criteria
C0680251
other trial
Item
Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
boolean
C2348568
Contraindication LDAC
Item
Administration of LDAC is clinically contraindicated
boolean
C1301624
C0010711
AML M3 APL
Item
Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
boolean
C0023487
CML blast crisis
Item
Patients with blast crisis of chronic myeloid leukaemia
boolean
C0023473
C0005699